Fosun is set to extend its reach in new deal with Gland Pharma

By Catherine Sturman
Fosun Pharma will now be gaining a 74% in Gland Pharma, in a deal which has been in the pipeline since July. The deal has been revised from 86%, removin...

Fosun Pharma will now be gaining a 74% in Gland Pharma, in a deal which has been in the pipeline since July. The deal has been revised from 86%, removing any further regulatory obstacles and go through the more rapid process under the foreign direct investment policy.

Costing over $1 billion, Gland Pharma will remain headquartered in Hyderabad and see the company further its ambitions within pharmaceutical manufacturing, and grow its services within India and the US. In 2003, Gland Pharma became the first company in India to get US Food and Drug Administration (“FDA”) approval for pharmaceutical liquid injectable products.

Gland Pharma’s world-class manufacturing facilities have also received approvals from a number of key medical regulatory agencies around the globe including those in Australia, Germany, and the UK, as well as the World Health Organization (“WHO”).

Related stories

Mr. Chen Qiyu, Chairman of Fosun Pharma said: “Gland Pharma’s management team, along with the support from KKR, has done a tremendous job of growing the business to become the global leader in Generics Injectables Industry.

The deal will greatly strengthen Fosun Pharma’s global presence and accelerate our speed of internationalization. It will enable us to provide more high-quality products and services to our patients worldwide.”

The two pharmaceutical manufacturers are expected to integrate production lines and synergize innovation in developing biopharmaceutical products. Fosun Pharma would also be able to further explore the international market by leveraging Gland Pharma’s research capability and India’s preferential policies upon generic drugs.  

Share

Featured Articles

Comarch Diagnostic Point Boost for European Health Insurance

Healthtech specialist Comarch introduces Diagnostic Point, designed to improve health insurance across European markets

McKinsey: Women More Likely to die of Heart Attack Than Men

McKinsey Health Institute's Lucy Pérez says cardiovascular disease top killer of women yet physicians don't know their heart attack symptoms are different

Novo Nordisk Buys $1bn Cardior in CardioVascular Move

As Novo Nordisk expands into heart medicines, we profile the Danish pharma giant who in 1923 was the first to make insulin commercially available

Shoddy Chinese Syringes Sees BD Ramp-up Production

Procurement & Supply Chain

AI Tool 'Picks up Early-stage Breast Cancers Doctors Missed'

Technology & AI

AstraZeneca Buys $2bn Fusion in Next-gen Cancer Drugs Move

Medical Devices & Pharma